Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye implant for diabetes? trial pulled before it began

NCT ID NCT04198350

Disease control Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study aimed to transplant insulin-producing cells into the front chamber of the eye for people with type 1 diabetes and poor vision. The goal was to see if the procedure was safe for the eye. However, the trial was withdrawn before enrolling any participants, so no results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pancreatic islet cells
What this could lead to
If successful, this could offer a new site for islet transplantation, potentially improving diabetes control while preserving vision.
What could go wrong
The trial was withdrawn before any participants enrolled, so no data exists. The procedure requires lifelong immunosuppression, which carries serious risks. Vision complications are a major concern.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Started

Sep 2022

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * T1D participants that fulfill criteria for islet transplantation * Systemic immunosuppression * At least one eye with VA from HM to 0.1, and fellow eye with equal or better VA * Age ≥ 18 years * Normal cornea with good visualization of the anterior segment * Participant not eligible or with no wish for standard pancreatic islet into the hepatic portal system or pancreas transplantation * Participants who have recently been involved in research or who are actively involved in research may be recruited at the discretion of the chief investigator if the active research has no impact on glucose self-management. Exclusion Criteria: * VA below HM or above 0.1 * Neovascular glaucoma * Iris neovascularization * Ongoing treatment with intraocular anti-VEGF or steroids (and no injection within 4 weeks) in the study eye and no anticipated need for therapy during study period. * Ongoing retinal laser photocoagulation * Signs of current infection or inflammation * Intraocular surgery within 3 months * Previous or planned anterior segment surgery for glaucoma * Poor visualization of the anterior chamber

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Type 1 diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus vision disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Type 1 diabetes Visual impairment

Contacts and locations

Locations

  • Imperial College London, Imperial College Healthcare NHS Trust

    London, W2 1PG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.